-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Outperform on Cytokinetics, Lowers Price Target to $100

Benzinga·11/05/2026 19:18:09
Diffusion vocale
Leerink Partners analyst Roanna Ruiz maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and lowers the price target from $103 to $100.